PE20211056A1 - Anticuerpos monoclonales antirrabicos y coctel de los mismos - Google Patents
Anticuerpos monoclonales antirrabicos y coctel de los mismosInfo
- Publication number
- PE20211056A1 PE20211056A1 PE2021000646A PE2021000646A PE20211056A1 PE 20211056 A1 PE20211056 A1 PE 20211056A1 PE 2021000646 A PE2021000646 A PE 2021000646A PE 2021000646 A PE2021000646 A PE 2021000646A PE 20211056 A1 PE20211056 A1 PE 20211056A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- peptide
- polypeptide
- cocktail
- antibodies
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 10
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 241000711798 Rabies lyssavirus Species 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invencion se refiere a un anticuerpo monoclonal que comprende: a) CDRH1 que comprende un peptido de SEC ID NO: 1; b) CDRH2 que comprende un peptido de SEC ID NO: 2; c) CDRH3 que comprende un peptido de SEC ID NO: 3; d) CDRL1 que comprende un peptido de SEC ID NO: 4; e) CDRL2 que comprende un peptido de SEC ID NO: 5 y f) CDRL3 que comprende un peptido de SEC ID NO: 6. Ademas, el anticuerpo monoclonal comprende: i) una region variable de la cadena pesada que comprende un polipeptido de SEC ID NO: 7, ii) una region variable de la cadena ligera que comprende un polipeptido de SEC ID NO: 8; iii) la cadena pesada que comprende un polipeptido de SEC ID NO: 9, y iv) la cadena ligera que comprende un polipeptido de SEC ID NO: 10. Tambien se refiere a un coctel de anticuerpos, una composicion, un kit y un proceso de preparacion del anticuerpo monoclonal. Dicho anticuerpo se une y neutraliza el virus de la rabia (RABV), previniendo la enfermedad causada por dicho virus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821041598 | 2018-11-02 | ||
| PCT/IB2019/059118 WO2020089742A1 (en) | 2018-11-02 | 2019-10-24 | Anti-rabies monoclonal antibodies and cocktail thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211056A1 true PE20211056A1 (es) | 2021-06-07 |
Family
ID=68655573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000646A PE20211056A1 (es) | 2018-11-02 | 2019-10-24 | Anticuerpos monoclonales antirrabicos y coctel de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3873526B1 (es) |
| CN (1) | CN113226372A (es) |
| BR (1) | BR112021008240A2 (es) |
| EC (1) | ECSP21039816A (es) |
| MA (1) | MA54075A (es) |
| MX (1) | MX2021005029A (es) |
| PE (1) | PE20211056A1 (es) |
| PH (1) | PH12021550987A1 (es) |
| WO (1) | WO2020089742A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103998059B (zh) | 2011-09-30 | 2016-01-20 | 赛特瑞恩股份有限公司 | 用于中和狂犬病病毒的结合分子 |
| DK3220947T3 (da) * | 2014-11-18 | 2020-11-30 | Humabs Biomed S A | Antistoffer som potent neutraliserer rabiesvirus og øvrige lyssavirusser og anvendelser deraf |
| US10450367B2 (en) * | 2015-08-13 | 2019-10-22 | University Of Massachusetts | Human antibodies against rabies and uses thereof |
-
2019
- 2019-10-24 MX MX2021005029A patent/MX2021005029A/es unknown
- 2019-10-24 PE PE2021000646A patent/PE20211056A1/es unknown
- 2019-10-24 CN CN201980086084.6A patent/CN113226372A/zh active Pending
- 2019-10-24 BR BR112021008240-9A patent/BR112021008240A2/pt unknown
- 2019-10-24 MA MA054075A patent/MA54075A/fr unknown
- 2019-10-24 WO PCT/IB2019/059118 patent/WO2020089742A1/en unknown
- 2019-10-24 EP EP19809146.4A patent/EP3873526B1/en active Active
-
2021
- 2021-04-30 PH PH12021550987A patent/PH12021550987A1/en unknown
- 2021-06-02 EC ECSENADI202139816A patent/ECSP21039816A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3873526B1 (en) | 2024-09-04 |
| WO2020089742A1 (en) | 2020-05-07 |
| BR112021008240A2 (pt) | 2021-10-26 |
| ECSP21039816A (es) | 2021-09-30 |
| MX2021005029A (es) | 2021-07-15 |
| MA54075A (fr) | 2022-02-09 |
| EP3873526A1 (en) | 2021-09-08 |
| CN113226372A (zh) | 2021-08-06 |
| PH12021550987A1 (en) | 2021-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500538A5 (es) | ||
| HRP20201503T1 (hr) | MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79 | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| IL259940B2 (en) | A method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists | |
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| CO2020014727A2 (es) | Anticuerpo anti proteína reguladora de señales alfa sirpαlfa | |
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| JP2019504032A5 (es) | ||
| NZ610153A (en) | Novel anti-dr5 antibody | |
| PE20230415A1 (es) | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SINDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) | |
| ES2430068T3 (es) | Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| RS52345B (en) | ANTI-IL-23P19 ANTIBODY MANUFACTURED BY GENETIC ENGINEERING | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
| RS52509B (en) | ANTI-IL-17 ANTITELA | |
| PE20221151A1 (es) | Anticuerpos anti-cd96 y sus metodos de uso | |
| PE20080181A1 (es) | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer | |
| PE20121023A1 (es) | Anticuerpos e inmunoconjugados | |
| RS53685B1 (en) | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS | |
| PE20161439A1 (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos | |
| ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
| AR082194A1 (es) | Anticuerpos anti-ron | |
| PE20221865A1 (es) | Anticuerpos contra el virus de la fiebre amarilla y metodos de su generacion y uso |